Hansen Gwenn sold $108K of NRIX
Hansen Gwenn (Chief Scientific Officer) sold 5,394 shares of Nurix Therapeutics, Inc. (NRIX) at $20.00 ($0.11M total) on 2026-06-25 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
An officer (Chief Scientific Officer) executed an open-market sale of 5,394 shares at $20.00/share; holdings after sale were 115,005 shares.
Market read
Traders may monitor insider activity, but this specific disclosure is a planned 10b5-1 sale without new company fundamentals.
What to watch
The sale size is modest relative to typical institutional flows, and 10b5-1 plans are designed to reduce timing-based signaling; without additional filings, the signal-to-noise is low.
Background
The article is a SEC Form 4 insider transaction disclosure for Nurix Therapeutics (NRIX).
Ticker impact
Nurix Therapeutics insider Hansen Gwenn sold 5,394 shares at $20.00/share under a 10b5-1 plan on 2026-06-25.
Likely limited near-term impact; any effect is typically absorbed unless accompanied by other negative company-specific news.
The filing is primary-source and time-stamped, but the transaction is explicitly under a pre-arranged 10b5-1 plan and lacks any accompanying operational/regulatory catalyst.
Market effects
No sector read-through; this is company-specific insider liquidity information.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as reduced confidence, potentially pressuring sentiment.
Key entities
- issuerNurix Therapeutics, Inc.
Company whose insider transaction is disclosed via SEC Form 4.
- insiderHansen Gwenn
Chief Scientific Officer who sold shares under a pre-arranged 10b5-1 plan.
